559 Efficacy of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis

View at publisher Summarise with VIRAT
Authors: Diego Pichardo-Rojas, Jose Alfonso Alvarez Castro, Yenny Viviana Pinzón, Nathalia Alfonso Lozano, Andres Alfredo Bezares Ristori, Pavel Pichardo Rojas
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Idiopathic intracranial Hypertension (IIH) is a debilitating condition characterized by elevated intracranial pressure without a detectable cause, often leading to visual impairment and chronic headache. GLP-1 receptor agonists (GLP-1 RAs), originally developed for diabetes and weight loss, have emerged as a potential therapeutic option. METHODS: We searched PubMed, EMBASE, and clinical trial registries up to March 2025 for studies reporting outcomes of GLP-1 RAs in IIH. Primary outcomes included: (1) rate of papilledema at 6 months, (2) change in monthly headache days at 3 months, and (3) incidence of new visual disturbances at 6 months. Pooled analyses were performed using random-effects models, and heterogeneity was assessed with I2 statistics. RESULTS: Out of 133 papers, 5 studies were included; 2 randomized controlled trials and 3 propensity score matched studies. Our sample population totaled 2118 patients. GLP-1 RA therapy significantly reduced the rate of papilledema at 6 months compared to controls (RR = 0.46, 95% CI: 0.34–0.62, I2 = 39%, p < 0.00001). A significant reduction in monthly headache days was also observed (mean difference = -3.67 days; 95% CI: -6.28 to -1.07, I2 = 0%, p = 0.006). GLP-1 RAs additionally reduced the risk of new visual disturbances at 6 months (RR = 0.43; 95% CI: 0.27–0.71, I2 = 49%, p = 0.0008). CONCLUSIONS: GLP-1 RAs significantly improve key clinical outcomes in IIH, including reduction in papilledema, headache frequency, and risk of visual deterioration. These findings support their potential role as disease-modifying agents in IIH management. Our analysis is limited by the use of different types of GLP-1 RAs and limited follow-up. Larger randomized trials are warranted to evaluate the benefits of GLP1-RAs and define optimal treatment regimens.

Fields of Study & Subjects

Cerebral Venous Sinus Thrombosis Glaucoma and retinal disorders Migraine and Headache Studies

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
168–168
Publication date
26 March 2026
Language
EN